May 21, 2019
STOCKHOLM, May 21, 2019 /PRNewswire/ -- "The initiation of the filing process for melflufen in the US is a major milestone for Oncopeptides." Financial overview January 1 – March 31, 2019 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 122.2 M (loss: 62.0) Loss per...
Source URL: https://www.prnewswire.com:443/news-releases/oncopeptides-ab-interim-report-q1-2019-300853766.html
|
